Publication:
CD8+ Cytotoxic Immune Infiltrate in Non-Muscle Invasive Bladder Cancer: A Standardized Methodology to Study Association with Clinico-Pathological Features and Prognosis.

dc.contributor.authorMasson-Lecomte, Alexandra
dc.contributor.authorMaillé, Pascale
dc.contributor.authorPineda, Silvia
dc.contributor.authorSoyeux, Pascale
dc.contributor.authorSagrera, Ana
dc.contributor.authorRava, Marta
dc.contributor.authorde Maturana, Evangelina Lopez
dc.contributor.authorMárquez, Mirari
dc.contributor.authorTardón, Adonina
dc.contributor.authorCarrato, Alfredo
dc.contributor.authorKogevinas, Manolis
dc.contributor.authorde la Taille, Alexandre
dc.contributor.authorHartmann, Arndt
dc.contributor.authorMalats, Nuria
dc.contributor.authorReal Arribas, Francisco
dc.contributor.authorAllory, Yves
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderAsociación Española Contra el Cáncer
dc.contributor.funderNIH - National Cancer Institute (NCI) (Estados Unidos)
dc.contributor.funderEuropean Association of Urology
dc.date.accessioned2024-02-20T13:24:08Z
dc.date.available2024-02-20T13:24:08Z
dc.date.issued2019-08-16
dc.description.abstractBACKGROUND Major interest lies in the evaluation of immune infiltrate in bladder cancer. CD8+ cytotoxic lymphocytes are key effectors of adaptive immune response. OBJECTIVES The aims of the study were to set up a standardized methodology for CD8+ lymphocytes estimation in NMIBC and investigate how intra-tumoral heterogeneity influences CD8+ immune infiltrate. METHODS We considered 995 NMIBC included in the Spanish Bladder Cancer (SBC)/EPICURO Study. Duplicate 0.6mm TMA spots and paired full sections (FS) for 50 selected cases were double stained with anti-pan cytokeratin antibody and anti-CD8 antibody. Slides were digitalized and CD8+ cells were automatically counted after tissue recognition (tumor vs stroma). Spatial heterogeneity was assessed and a resampling strategy was applied to estimate the proper number of 0.6mm TMA spots providing an adequate CD8+ cell estimate. Association between CD8+ count and expression of urothelial differentiation markers was estimated. Cox regression models were performed to assess association between CD8+ cell count and risk of recurrence and progression. RESULTS Microscopic examination of full sections showed spatial heterogeneity for CD8+ infiltrates. Simulation analyses demonstrated that 5 TMA regions provided a correct sampling of tumor and stromal compartments in Ta while 2 and 6 TMA regions were necessary in T1, respectively. CD8+ cells infiltration was associated with stage, regardless of the histological compartment analyzed (median CD8+ /mm2 were 25/mm2 and 129/mm2 in tumor and stroma respectively in Ta and 111/mm2 and 344/mm2 in T1; p-value = 0.006). CD8+ infiltration in tumor compartment was significantly associated with low FGFR3 expression. CD8+/mm2 count in the tumor compartment was not associated with prognosis. CONCLUSION Differences identified between Ta and T1 tumours supported the hypothesis that rigorous efforts should be placed in proper study design. These results provide a new framework to investigate microenvironment complexity in bladder cancer.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipThe work was partially supported by Fondo de Investigaciones Sanitarias (FIS, #PI00-0745, #PI05-1436, and #PI06-1614) and Red Tematica de Investigacion Cooperativa en Cancer (RTICC, #RD12/0036/0050 and #RD12/0036/0034), Instituto de Salud Carlos III; and Asociacion Espanola Contra el Cancer (AECC), Spain; the Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, USA (Contract NCI NO2-CP-11015); and EU-FP7-HEALTH-F2-2008-201663-UROMOL and EU-7FP-HEALTH-TransBioBC #601933. AML was funded by a fellowship of the European Urological Scholarship Program from the European Association of Urology (EUSP Scholarship S-01-2013).es_ES
dc.format.number2es_ES
dc.format.page159es_ES
dc.format.volume5es_ES
dc.identifier.citationBladder Cancer . 2019;5(2):159-169es_ES
dc.identifier.doi10.3233/blc-180206es_ES
dc.identifier.issn2352-3727es_ES
dc.identifier.journalBladder cancer (Amsterdam, Netherlands)es_ES
dc.identifier.pmchttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503287/
dc.identifier.pubmedID36157135es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/18536
dc.language.isoenges_ES
dc.publisherIOS Press
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI00-0745es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI05-1436es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI06-1614es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/RD12/0036/0050es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/RD12/0036/0034es_ES
dc.relation.publisherversionhttps://doi.org/10.3233/blc-180206.es_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Grupos de investigación::Grupo de Carcinogénesis Epiteliales_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleCD8+ Cytotoxic Immune Infiltrate in Non-Muscle Invasive Bladder Cancer: A Standardized Methodology to Study Association with Clinico-Pathological Features and Prognosis.es_ES
dc.typejournal articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublicatione90c1af5-4bfd-42de-af72-ef7ead52074c
relation.isAuthorOfPublicationd61ef7a1-b898-4ab4-a595-55eca1e382e7
relation.isAuthorOfPublication803aa5ee-1ebf-4697-a92a-5918e85b43c7
relation.isAuthorOfPublication62d13a40-e75d-49b1-bb0a-f54a4146ad3e
relation.isAuthorOfPublication.latestForDiscoverye90c1af5-4bfd-42de-af72-ef7ead52074c
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublication453a1189-9bca-4be8-8d60-695f50fe028b
relation.isFunderOfPublicationb589134c-ce3e-4f64-a3f5-83d0a7eb706a
relation.isFunderOfPublicatione1efc2b6-736a-4cbd-b0ac-b60e07d40860
relation.isFunderOfPublication.latestForDiscovery7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isPublisherOfPublicationb6726c7c-7316-4bbb-b71a-e5e765babe7f
relation.isPublisherOfPublication.latestForDiscoveryb6726c7c-7316-4bbb-b71a-e5e765babe7f

Files